Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018
— Presentation to be webcast on
www.exelixis.com —
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will provide an overview of the company at the Morgan Stanley Global Health Care Conference taking place September 12-14
in New York, NY. The Exelixis presentation is scheduled for 1:05 PM EDT / 10:05 AM PDT on Wednesday, September 12, 2018.
To access the webcast link, log onto
www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please
connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download
that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives
to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early
work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for
our continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products,
CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products
and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are
supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to
deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. In July 2018, Exelixis was
added to the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
For more information about Exelixis, please visit
http://www.exelixis.com, follow @ExelixisInc
on Twitter or like
Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.
Investors Contact:
Exelixis, Inc.
Susan Hubbard, 650-837-8194
EVP, Public Affairs and Investor Relations
shubbard@exelixis.com
or
Media Contact:
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcommunications.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180905005913/en/